Human Embryonic Stem Cell Lines Now Commercially Available
By Biotechdaily staff writers
Posted on 21 May 2007
Researchers wishing to work with human embryonic stem cells (hES) now have a new commercial source of licensed, low passage cell lines. Posted on 21 May 2007
Millipore Corp. (Billerica, MA, USA) has begun marketing two hES cell lines, MEL-1 and MEL-2. Both lines have been tested extensively with Millipore's HEScGRO media for human embryonic stem cell culture. The cell lines are provided at early passage (p10–p12), ideal for maximizing the stable lifespan of the cell line and ensuring extended research time in a stable, pluripotent state. The cells grow as well-defined colonies, with compact cells displaying high nuclear to cytoplasmic ratios and prominent nucleoli.
Millipore developed the MEL lines in collaboration with the Australian Stem Cell Centre (Clayton, Victoria) under license from the Australian National Health and Medical Research Council. A June 2006 agreement between Millipore and the Australian Stem Cell Centre allows Millipore to distribute and market these stem cell lines in all countries outside of Australia.
Related Links:
Millipore Corporation
Australian Stem Cell Centre